RGLS Insider Trading Activity and SEC Form 4 Filings
RGLS insider trading summary
No open-market insider purchases or sales of Regulus Therapeutics Inc. (RGLS) have been reported on SEC Form 4 in the past 12 months.
Latest RGLS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 3, 2025 | Preston Klassen | President & Head of R & D | Buy | $96K (12,000 @ $7.99) |
| Jan 30, 2025 | David Baltimore | Insider | Buy | $21K (19,610 @ $1.06) |
| Jan 30, 2025 | Joseph P Hagan | Chief Executive Officer | Buy | $54K (50,000 @ $1.09) |
| Jan 14, 2025 | Crispina Calsada | Chief Financial Officer | Sell | $6K (5,088 @ $1.26) |
| Jan 14, 2025 | Joseph P Hagan | Chief Executive Officer | Sell | $15K (11,764 @ $1.26) |
| Jan 14, 2025 | Christopher Ray Aker | Sr. VP & General Counsel | Sell | $6K (5,088 @ $1.26) |
| Jan 13, 2025 | Preston Klassen | President & Head of R & D | Sell | $40K (31,445 @ $1.26) |
| Jan 13, 2025 | Christopher Ray Aker | Sr. VP & General Counsel | Sell | $49K (38,547 @ $1.26) |
| Jan 13, 2025 | Crispina Calsada | Chief Financial Officer | Sell | $49K (38,716 @ $1.26) |
| Jan 13, 2025 | Joseph P Hagan | Chief Executive Officer | Sell | $146K (115,290 @ $1.26) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.